Source:http://linkedlifedata.com/resource/pubmed/id/17693000
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
37-38
|
| pubmed:dateCreated |
2007-9-7
|
| pubmed:abstractText |
Although the theoretical concern of genetic recombination has been raised related to the use of live attenuated flavivirus vaccines [Seligman, Gould, Lancet 2004;363:2073-5], it has little foundation [e.g., Monath TP, Kanesa-Thasan N, Guirakhoo F, Pugachev K, Almond J, Lang J, et al. Vaccine 2005;23:2956-8]. To investigate biological effects of recombination between a chimeric yellow fever (YF) 17D/Japanese encephalitis (JE) vaccine virus (ChimeriVax-JE) and a wild-type flavivirus Kunjin (KUN-cDNA), the prM-E envelope protein genes were swapped between the two viruses, resulting in new YF 17D/KUN(prM-E) and KUN/JE(prM-E) chimeras. The prM-E genes are easily exchangeable between flavivirues, and thus the exchange was expected to yield the most replication-competent chimeras, while other rationally designed recombinants would be more likely to be crippled or non-viable. The new chimeras proved highly attenuated in comparison with the KUN-cDNA parent, as judged by plaque size and growth kinetics in cell culture, low viremia in hamsters, and reduced neurovirulence/neuroinvasiveness in mice. These data provide strong experimental evidence that the potential of recombinants, should they ever emerge, to cause disease or spread (compete in nature with wild-type flaviviruses) would be indeed extremely low.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0264-410X
|
| pubmed:author |
pubmed-author:BrownNathanN,
pubmed-author:CatalanJohnJ,
pubmed-author:GuirakhooFarshadF,
pubmed-author:KhromykhAlexander AAA,
pubmed-author:MitchellFrederick SFS,
pubmed-author:MonathThomas PTP,
pubmed-author:OcranSimeon WSW,
pubmed-author:PugachevKonstantin VKV,
pubmed-author:RumyantsevAlexander AAA,
pubmed-author:SchwaigerJuliaJ,
pubmed-author:ZhangZhen-xiZX
|
| pubmed:issnType |
Print
|
| pubmed:day |
17
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
6661-71
|
| pubmed:meshHeading |
pubmed-meshheading:17693000-Animals,
pubmed-meshheading:17693000-Base Sequence,
pubmed-meshheading:17693000-Body Weight,
pubmed-meshheading:17693000-Cell Line,
pubmed-meshheading:17693000-Cricetinae,
pubmed-meshheading:17693000-Female,
pubmed-meshheading:17693000-Flavivirus,
pubmed-meshheading:17693000-Genetic Engineering,
pubmed-meshheading:17693000-Genome, Viral,
pubmed-meshheading:17693000-Humans,
pubmed-meshheading:17693000-Kinetics,
pubmed-meshheading:17693000-Mice,
pubmed-meshheading:17693000-Vaccines, Attenuated,
pubmed-meshheading:17693000-Virulence,
pubmed-meshheading:17693000-Virus Replication,
pubmed-meshheading:17693000-West Nile Virus Vaccines
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE).
|
| pubmed:affiliation |
Acambis, Inc., 38 Sidney St., Cambridge, MA 02139, USA. konstantin.pugachev@acambis.com
|
| pubmed:publicationType |
Journal Article
|